The Working Party endorsed this document at its 10th Meeting in June 2012. It is intended to provide information on the outcomes and developments of the WPMN related to the safety of manufactured nanomaterials.

The purpose of the agenda item 4 (the Tour de Table) is to give each delegation the opportunity to describe recent or planned national initiatives and/or events related to the safety of manufactured nanomaterials. This will facilitate the implementation of the projects of the WPMN by allowing delegations to share their experiences and preoccupations with respect to safety, and will identify opportunities for future co-operation and co-ordination.

In considering the Tour de Table, each delegation was invited to prepare a short written paper. It was recommended that the information in these papers be organised, where possible, under the headings identified below, while recognising that not all delegations would be able to supply information under each heading.

1) Highlight of developments since the 9t meeting of the WPMN

2) Work completed, underway or planned

1. Any national regulatory developments on human health and environmental safety including recommendations or discussions related to adapting existing regulatory systems or the drafting of laws/ regulations/ guidance materials;

2. Developments related to voluntary or stewardship schemes;

3. Information on any risk assessment decisions;

4. Information on any developments related to good practice documents;

5. Information on any developments related to Integrated Testing Strategies and/or Alternative test methods

6. Research programmes or strategies designed to address human health and/ or environmental safety aspects of nanomaterials;

7. Information on any public/ stakeholder consultation;

8. Information on research programmes or strategies which focus on life cycle aspects of nanomaterials, as well as positive and negative impacts on environment and health of certain nano-enabled applications. (You may wish to contact your colleagues participating in SG9.);

9. Information on any development related to exposure measurement and exposure mitigation

10. Additional Information

- Any consideration on the benefits of nanotechnologies;

- Consideration of ethical implications; and